Neurocrine Biosciences, Inc.
NBIX
$118.78
$1.911.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.28% | 36.68% | 102.04% | 92.29% | 477.66% |
| Total Depreciation and Amortization | 26.67% | 27.23% | 28.50% | 33.51% | 30.06% |
| Total Amortization of Deferred Charges | -200.00% | -- | -100.00% | 34,500.00% | 10,987.50% |
| Total Other Non-Cash Items | 167.75% | 171.44% | 96.94% | 87.21% | -50.23% |
| Change in Net Operating Assets | -120.89% | -168.09% | -307.96% | -768.09% | 209.96% |
| Cash from Operations | -17.90% | 52.71% | 16.37% | 79.07% | 153.40% |
| Capital Expenditure | -21.61% | -34.98% | -46.96% | -132.47% | -78.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 95.57% | 79.81% | 28.55% | -20.82% | -252.16% |
| Cash from Investing | 88.00% | 72.85% | 31.66% | -10.84% | -155.86% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -33.62% | 86.98% | 170.64% | 197.03% | 171.37% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -631.10% | -845.33% | -395.96% | -458.60% | 154.69% |
| Foreign Exchange rate Adjustments | -100.00% | -100.00% | 146.15% | 123.08% | 123.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -169.08% | -56.03% | -32.19% | -606.90% | 275.90% |